Table 2. Characteristics of newly treatment-eligible HIV-infected U.S. residents in NA-ACCORD, 2001–2009.

	Overall (N = 8,874)		Included in analysis of state contribution to ADAP budget (N = 1,082) *		Included in analysis of state ADAP waiting lists (N = 620) *
	N	%	N	%	N	%
Age at eligibility, years (median, IQR)	40	33–46	41	34–47	37	31–44
18–29	1,555	18	139	13	131	21
30–39	2,869	32	343	32	236	38
40–49	2,989	34	397	37	196	32
50–59	1,216	14	181	17	47	8
60+	245	3	22	2	10	1.6
Race/ethnicity
Black (non-Hispanic)	3,937	44	617	57	272	44
Hispanic	1,631	18	57	5	40	7
White (non-Hispanic)	2,944	33	382	35	293	47
Other (non-Hispanic)	362	4	26	2.4	15	2.4
Sex and transmission risk
Men who have sex with men	3,839	43	368	34	282	46
Male injection drug user	946	11	210	19	46	7
Male, heterosexual or other risk	1,764	20	162	15	145	23
Female injection drug user	387	4	115	11	12	1.9
Female, heterosexual or other risk	1,938	22	227	21	135	22
Eligibility criteria
CD4+ count 0–199 cell/uL	3,118	35	274	25	224	36
CD4+ count 200–349 cells/uL	5,464	62	775	72	380	61
Incident AIDS-defining illness (i.e., CD4+ count not <350 cells/uL)	292	3	33	3	16	2.6
Viral load at eligibility
501–999 copies/mL	152	1.7	12	1.1	6	1
1,000–9,999 copies/mL	1,299	15	156	14	56	9
10,000–99,999 copies/mL	3,743	42	464	43	248	40
100,000+ copies/mL	2,588	29	261	24	162	26
Missing	1,092	12	189	18	148	24

ART = antiretroviral therapy, IQR = interquartile range. Percentages may not add up to 100 due to rounding.

^*See Figure 1 for details of study selection procedure.